Diabetes Is Not For The Faint Of Heart
This article was originally published in Pharmaceutical Approvals Monthly
Regulatory and commercial hurdles in the type 2 diabetes market have created a space where only the largest, most sophisticated companies can expect to compete.
You may also be interested in...
Two of the world’s largest pharmaceutical companies are teaming up to develop a treatment for type 2 diabetes, but the drug will have plenty of competitors with a better market position by the time it faces regulatory approval.
New treatments for Type 2 diabetes are driving the optimism underlying Bristol and AstraZeneca’s proposed acquisition for Amylin and are leading to a re-alignment of allies and competitors focused on the disease. Companies are enthusiastic about the vast opportunity, yet worried about the costs and risks of full-scale commitment to it.
Influence of expedited review pathways and regulatory incentives is on display in 2020’s novel approvals, which have a composition reassuringly consistent with recent years.